BMAL1 and non-Hodgkin lymphoma: In DLBCL, circadian genes CEBPA and its downstream target PER2 are highly deregulated,43 and BMAL1 (ARNTL) is epigenetically inactivated.44 Furthermore, genetic variants of CRY2 have been associated with a risk of non-Hodgkin’s lymphoma.